Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | -.--% | +79.28% |
Financials (USD)
Sales 2026 * | - | Sales 2027 * | - | Capitalization | 129M |
---|---|---|---|---|---|
Net income 2026 * | - | Net income 2027 * | - | EV / Sales 2026 * | - |
Net cash position 2026 * | - | Net cash position 2027 * | - | EV / Sales 2027 * | - |
P/E ratio 2026 * |
-
| P/E ratio 2027 * |
-
| Employees | 138 |
Yield 2026 * |
-
| Yield 2027 * |
-
| Free-Float | 98.11% |
Latest transcript on NGM Biopharmaceuticals, Inc.
1 day | -1.28% | ||
3 months | +4.76% | ||
6 months | +119.65% | ||
Current year | +79.28% |
Managers | Title | Age | Since |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 21-06-07 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | -.--% | - |
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.55% | 21.25B | |
-5.66% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- NGM Stock